Javascript är inaktiverat

Javascript verkar vara inaktiverat. Detta kommer att påverka sitens funktionalitet. Vänligen aktivera JavaScript eller återvänd till denna webbplats från en annan enhet.

24:e Svenska Kardiovaskulära Vårmötet 2023

26-28 april

Werköföreläsare 2023

Årets Werköföreläsare är Prof. Massimo Piepoli från Milano, Italien.

Werköföreläsnings hålls i samband med Svenska Kardiovaskulära Vårmötets invigning.
Onsdag 26 april klockan 17.05.

Werköföreläsningen är Vårmötets högtidsföreläsning.
Läs mer här om Lars Werkö och tidigare föreläsare.

Prof. Massimo Piepoli holds the role of Director of the Cardiology Unit at the Policlinico San Donato Hospital (University of Milan), as well as being Affiliated at the Sant'Anna School of Advanced Studies, and the G. Monasterio Foundation, large Italian national reference centers, and at the Department of Preventive Cardiology, University of Wroclaw, Poland.

Graduated in Medicine and Surgery and specialized in Cardiology at the University of Pavia in 1987 and 1991 respectively, in 1996 he obtained the Philosophy Doctor Degree at Imperial College London.

Piepoli's research examines the pathophysiology of heart failure and the role of neuro-hormonal imbalance in the evolution of heart failure, as well as the mechanisms of cardiovascular disease, innovation in diagnostics and therapy. His research results (Scopus 2023: H index 115; Total citations 134,712; Documents cited 697) testify to the results of his clinical research methodology and attitude towards a multidisciplinary approach. Several research projects are based on international collaborative networks and have been able to attract funds that have ensured their pursuit and realization. He is the author of 351 articles in peer-reviewed journals (Pubmed), contributed to the drafting of 31 European guidelines, 53 position papers, 136 invited lectures to international conferences, publisher of 12 books.

Since 2017, winner of international selection, he has been appointed Editor in Chief de European Journal of Cardiovascular Prevention, which under his guidance has seen his IF grow from 3.3 to 8.5; he is also a member of the Editorial Board of the European Heart Journal, and of the European Journal of Heart Failure. From 2020 he was also elected to the board of the European Society of Cardiology with the role of Vice President.